Alkermes Announces Positive Results From Study of ALKS 5461 for Treatment of Major Depressive Disorder

Safety and Tolerability Profile of ALKS 5461 Confirmed in FORWARD-1 Study, a Supportive Study in the FORWARD Phase 3 Pivotal Program Dosing Regimen Confirmed; Efficacy Data Showed Statistically Significant Improvements in Depression Scores Beginning at Week One and Continuing Through Eight-Week Treatment Period DUBLIN–(BUSINESS WIRE)–Jan. 6, 2015– Alkermes plc (NASDAQ: ALKS) today announced topline results […]